Meta Pixel

Percheron Therapeutics (ASX: PER)

Australia|Biotechnology

Overview

Percheron Therapeutics Limited (ASX: PER)
www.PercheronTx.com 

Percheron Therapeutics is an ASX-listed biotech company, focused on the developmenty of new therapies for cancer and rare diseases.

The company's lead program is HMBD-002, which works by activating the body's own immune system to fight cancer, a field known as immuno-oncology. This is a promising area at the cutting edge of cancer research and has already yielded a number of multi-billion-dollar pharmaceutical products. However, Percheron's drug is well-differentiated and has the potential to combine well with a wide range of existing therapies.

HMBD-002 has completed a phase I clinical trial in the United States. The trial showed the drug to be very safe and well-tolerated and provided some promising signals of potential efficacy in multiple forms of cancer.

Percheron aims to commence an international phase II human trial of HMBD-002 in CY2026. The planned trial will address several cancer types in parallel, and the prioritised groups currently include breast cancer, lung cancer, oesophageal cancer, and endometrial cancer. 

 

Why Invest?

Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.



Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac commodo enim lacinia at.



Morbi posuere tortor vitae sapien faucibus auctor. Donec nulla ipsum, aliquet non bibendum sit amet, viverra non metus. Sed blandit efficitur orci, id dignissim eros.



Donec sollicitudin massa ut tellus gravida, ut luctus lacus maximus. Maecenas porttitor a tellus ac sagittis. Suspendisse potenti. Donec mauris sem, tristique a ipsum vitae, pretium facilisis libero. Nullam interdum mauris in euismod pretium. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nunc felis lectus, ornare a nunc eu, convallis suscipit elit. Donec at magna non orci maximus mollis. Cras commodo venenatis lectus vel fringilla.

Proin mollis, magna consequat placerat tempus, lectus dui porttitor augue, eget vulputate orci augue nec nisl. Integer sagittis vitae nibh vitae finibus. Vestibul

Directors and Senior Management

Cras eleifend purus vitae mattis imperdiet.



Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.

Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.



Fusce scelerisque massa sit amet turpis rutrum semper.

Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.



Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan enim, quis blandit lacus posuere at. Sed tincidunt congue blandit. Maecenas interdum quam in mauris condimentum luctus. Donec fermentum egestas risus vel cursus. Ut metus justo, rutrum vel sem ut, consequat laoreet ante. Nunc tincidunt viverra metus, tincidunt viverra elit iaculis sit amet. Integer ullamcorper hendrerit eleifend. Curabitur massa nisi, tempus eget fermentum quis, volutpat non sem. Integer id sagittis dolor. Donec nunc erat, maximus sed magna id, faucibus ultricies velit. Nunc lobortis eget urna at semper.



Donec sollicitudin, tortor ac interdum tempus, mi odio fringilla lacus, sit amet hendrerit mi purus vel nisi. Phasellus nulla ligula, congue quis ullamcorper eget, egestas id leo. Sed et rhoncus libero. Mauris tincidunt ultricies justo ut tincidunt. Nam rhoncus est non erat auctor mattis. Sed quis consectetur ma

Competitive Advantage

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.



Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.



Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.



Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.



Aenean nulla

Highlights & Milestones

Proin auctor bibendum ex, non condimentum tortor sodales vitae. Ut feugiat at lorem accumsan consequat.



Suspendisse ac condimentum ipsum, sit amet auctor dui. Aliquam pretium justo in commodo varius.



Pellentesque elementum felis non urna vulputate, non posuere metus suscipit.

Aenean lacinia id quam a lobortis. Cras nibh lorem, vulputate eget purus elementum, pharetra condimentum elit.



Quisque et sagittis ex, vitae ultrices nulla. Vivamus dapibus blandit libero, et scelerisque dui ullamcorper ut. Vivamus ut molestie ex. Integer eget tempus mauris. Quisque volutpat pulvinar urna, posuere pharetra ex auctor vel. Sed id lacus tortor. Proin nisl turpis, tempus a leo in, lacinia volutpat orci.



Aenean nulla nibh, porta a dignissim vitae, laoreet vitae lacus. Nunc in aliquet urna. Vivamus vel turpis a mi consequat venenatis. Pellentesque tincidunt ante ut urna accumsan lacinia. Sed sed enim volutpat, malesuada metus ut, lobortis lectus. Sed vulputate fringilla justo,

See more exiting opportunities on CapitalHQ

Pictor

Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...

flag_new zealand
New Zealand NZD
Biotechnology Series B+

ProxyTwin

ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...

flag_australia
Australia AUD
Artificial Intelligence Seed Round

HorizonTwo Capital Partners

HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.

flag_australia
Australia AUD
Advanced Manufacturing Private Placement

The Insides Company

First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.

flag_new zealand
New Zealand AUD
Medical Devices Series A

DCARB

We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.

flag_australia
Australia CAD
Green Hydrogen Series B+

Grabba Technologies Pty Ltd

Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.

flag_australia
Australia AUD
Electronic Equipment & Instruments Private Placement

Join over 45,000+ sophisticated investors

Join Now